The Pharmacy Times® Digestive Health Resource Center is a comprehensive resource for clinical news and expert insights on issues related to health of the digestive system, including Crohn disease, inflammatory bowel disease, irritable bowel syndrome, and ulcerative colitis.
March 25th 2025
Pharmacists can promote prevention through the implementation of antimicrobial stewardship initiatives and advocate for fecal microbiota transplant.
Strategies for Integrating Biologic Therapy Into the Management of Eosinophilic Esophagitis
1.5 Credits / Immunology, Gastroenterology
View More
Navigating Next-Generation Therapies for the Management of Acid-Related Disorders
1.5 Credits / Gastroenterology
View More
Biologic Therapy for the Management of Eosinophilic Esophagitis in Children: The Evolving Treatment Paradigm
1.5 Credits / Gastroenterology, Immunology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Foundations in the Management of Eosinophilic Esophagitis: Pathophysiology, Clinical, Economic, and Quality of...
1.0 Credit / Gastroenterology, Immunology
View More
Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
1.0 Credit / Gastroenterology, Immunology, Rare Diseases
View More
The Evolving Treatment Paradigm for the Management of Eosinophilic Esophagitis and the Future of Oral Therapie...
1.0 Credit / Gastroenterology, Immunology
View More
The Role of the Community Pharmacist in the Management of Eosinophilic Esophagitis
1.0 Credit / Gastroenterology, Immunology
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Optimizing Treatment Strategies: A Comprehensive Approach to Primary Biliary Cholangitis and Pruritus
1.5 Credits / Hematologic Cancer, Hematology, Oncology
View More
Partnership Aims to Bring Novel Gastroenterology Therapies to Worldwide Market
May 20th 2019Parvus Therapeutics and Genentech have entered into a worldwide collaboration and licensing agreement for the development, manufacturing, and commercialization of treatments for inflammatory bowel disease, autoimmune liver diseases, and celiac disease using nanomedicines (Navacim) developed by Parvus.
Read More
FDA OKs Rifamycin for Travelers' Diarrhea Caused by Noninvasive E coli
November 17th 2018Rifamycin's effectiveness was shown in a randomized, placebo-controlled clinical trial during which the drug significantly reduced symptoms of travelers’ diarrhea in adults afflicted with the condition in Guatemala and Mexico.
Read More